TP53 and neoplasm: In the NSCLC cancer patients from the non-curative cohort where the data were available, the baseline value of hPG80 was not significantly different according to the smoking status (active, n = 20; former, n = 22; never, n = 5, P = 0.83), or the molecular status regarding TP53, K-RAS, or B-RAF mutations in the NSCLC cancer patients on tumor tissue or circulating tumor DNA (Suppl Tables 1, and Suppl Figs. 12 and 13).